This two-day event brings you the latest in achondroplasia research including, new pharmaceutical treatment developments and advancements in surgical treatment options. This is the only event in North America that brings together the leading pharmaceutical companies and some of the top world-renowned orthopedic experts specialized in treating achondroplasia – as well as, hypochondroplasia and other forms of dwarfism and skeletal dysplasia.
The health and safety of patients and conference attendees are our top priority. Due to COVID-19, this will be a hybrid event, thus offering attendees the option to attend in person or online. This conference will follow CDC, Maryland State, and Baltimore City guidelines.
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib,...
Read More